# Recent trends in the number of pathology samples indicating cancer in Northern Ireland

February 2022 update

#### **Further information**

Further information is available at: www.qub.ac.uk/research-centres/nicr **Phone:** +44 (0)28 9097 6028 **e-mail:** nicr@qub.ac.uk

#### **Acknowledgements**

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency and is based in Queen's University, Belfast.

NICR uses data provided by patients and collected by the health service as part of their care and support.







### **CONTENTS**

	<u>Page</u>
Summary	1
All persons	4
Males	6
Females	8
Ages 0-69	10
Ages 70 and over	12
Bowel cancer	14
Bowel cancer, screening age	16
Lung cancer	18
Female breast cancer	20
Female breast cancer, screening age	22
Prostate cancer	24
Upper gastrointestinal cancer	26
Gynaecological cancer	28
Head & neck cancer	30
Urinary cancer	32
Haematological cancer	34
Malignant melanoma	36
Non-melanoma skin cancer	38
Other cancer	40
Notes	42

# **SUMMARY**

# Recent trends in the number of pathology samples indicating cancer: February 2022


This summary provides an overview of recent trends in the number of pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) taken from January 2020 to February 2022 in Northern Ireland.

These trends are contrasted with the annual average number of pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of the Covid-19 restrictions on diagnostic cancer services.

Data are sourced from the four NHS pathology laboratories in NI (Belfast, Altnagelvin, Antrim, Craigavon), which are usually provided to NICR on a monthly basis. Altnagelvin laboratory is excluded from some analysis as a change in recording systems led to an undercount in the number of reported samples in Jan-Apr 2021.


#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 (Excludes Altnagelvin)

From March 2020 to February 2022 the number of pathological samples indicating cancer (ex NMSC) was 6.3% lower than the average number for the same time period in 2017-2019.




From March 2020 to February 2022 there was a 5.6% decrease in the number of samples among males and a 6.9% decrease among females compared to the same time period in 2017-2019. A decrease of 6.7% occurred in the number of samples among those aged 0-69 years, while there was a decrease of 5.8% in the number of samples among those aged 70 and older.

Compared to the annual average in 2017-2019, from March 2020 to February 2022 the number of pathology samples indicating lung cancer decreased by 25.8%. No cancer types had an increase in the number of samples between the two periods, while decreases of more than 10% were recorded for gynaecological cancer, head and neck cancer and non-melanoma skin cancer.



#### **RECENT CHANGES IN THE NUMBER OF SAMPLES (Includes Altnagelvin)**

There was a 0.8% decrease in the number of pathology samples indicating cancer in the twelve weeks up to 26/02/2022 compared to the average value in the equivalent weeks in 2017-2019.




Note: Date shown refers to the end date of the week in 2021-2022. Data for previous years refers to the equivalent Sat-Sun week in those years

In the twelve weeks up to 26/02/2022 there was a 0.6% decrease in the number of samples among males and a 0.9% decrease among females compared to the same time period in 2017-2019. A decrease of 4.7% occurred in

the number of samples among those aged 0-69 years, while there was an increase of 4.9% in the number of samples among those aged 70 and older.

Compared to the annual average in 2017-2019, in the twelve weeks up to February 2022 the number of pathology samples indicating lung cancer decreased by 22.1%. Increases were recorded for bowel cancer, prostate cancer, upper gastrointestinal cancer and melanoma, while decreases of more than 10% were recorded for non-melanoma skin cancer.




# ALL PERSONS: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


<sup>-6.3%</sup> 



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	1,222	1,257	939	1,083
Feb	1,033	1,101	996	1,025
Mar	1,137	1,064	1,265	
Apr	1,081	687	1,182	
Мау	1,287	778	1,240	
Jun	1,159	1,077	1,303	
Jul	1,119	1,026	1,082	
Aug	1,156	1,011	1,078	
Sep	1,160	1,169	1,228	
Oct	1,258	1,017	1,103	
Nov	1,228	1,174	1,271	
Dec	1,048	1,149	1,068	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>-0.8%</sup> 




147l**	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	345	331	
18/12/2021	332	328	
25/12/2021	115	292	
01/01/2022	299	137	
08/01/2022	303	250	
15/01/2022	308	313	
22/01/2022	343	316	
29/01/2022	323	351	
05/02/2022	343	323	
12/02/2022	260	310	
19/02/2022	292	251	
26/02/2022	303	334	

\* Average samples per year rounded to the nearest integer.

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-5.6%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	489	499	359	437
Feb	403	476	416	390
Mar	465	416	553	
Apr	443	242	466	
Мау	522	354	507	
Jun	469	458	520	
Jul	450	422	448	
Aug	444	394	418	
Sep	462	434	494	
Oct	512	398	418	
Nov	502	544	554	
Dec	412	470	412	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>-0.6%</sup> 



Weels commended to be wat *	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	137	124	
18/12/2021	134	125	
25/12/2021	50	114	
01/01/2022	111	71	
08/01/2022	128	103	
15/01/2022	128	133	
22/01/2022	142	148	
29/01/2022	131	138	
05/02/2022	139	131	
12/02/2022	99	123	
19/02/2022	115	106	
26/02/2022	134	123	


\* Average samples per year rounded to the nearest integer.

# FEMALE: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average





Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	733	758	580	646
Feb	631	625	580	635
Mar	673	648	712	
Apr	639	445	716	
Мау	765	424	733	
Jun	690	619	783	
Jul	669	604	634	
Aug	712	617	660	
Sep	697	735	734	
Oct	746	619	685	
Nov	726	630	717	
Dec	636	679	656	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average



-0.9%

Weels comments to boom **	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	208	207	
18/12/2021	198	203	
25/12/2021	65	178	
01/01/2022	188	66	
08/01/2022	175	147	
15/01/2022	180	180	
22/01/2022	201	168	
29/01/2022	192	213	
05/02/2022	204	192	
12/02/2022	161	187	
19/02/2022	177	145	
26/02/2022	168	211	


\* Average samples per year rounded to the nearest integer.

# AGED 0-69: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average

-6.7%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	740	711	556	597
Feb	624	622	598	589
Mar	683	633	749	
Apr	634	443	726	
Мау	758	455	713	
Jun	654	604	730	
Jul	640	560	608	
Aug	681	567	639	
Sep	677	666	710	
Oct	715	588	653	
Nov	695	680	739	
Dec	618	698	641	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average



-4.7%

147l**	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	202	212	
18/12/2021	202	175	
25/12/2021	63	193	
01/01/2022	183	80	
08/01/2022	187	151	
15/01/2022	181	181	
22/01/2022	213	165	
29/01/2022	196	193	
05/02/2022	213	179	
12/02/2022	159	185	
19/02/2022	172	140	
26/02/2022	182	197	


\* Average samples per year rounded to the nearest integer.

# AGED 70+: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average

-5.8%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	483	546	383	486
Feb	409	479	398	436
Mar	455	431	516	
Apr	447	244	456	
Мау	529	323	527	
Jun	504	473	573	
Jul	479	466	474	
Aug	475	444	439	
Sep	483	503	518	
Oct	543	429	450	
Nov	534	494	532	
Dec	430	451	427	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average



+4.9%

Waals commis to kon **	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	143	119	
18/12/2021	130	153	
25/12/2021	52	99	
01/01/2022	116	57	
08/01/2022	117	99	
15/01/2022	127	132	
22/01/2022	130	151	
29/01/2022	127	158	
05/02/2022	130	144	
12/02/2022	102	125	
19/02/2022	120	111	
26/02/2022	121	137	


\* Average samples per year rounded to the nearest integer.

### **BOWEL CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-0.7%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	126	152	106	134
Feb	112	120	125	115
Mar	120	109	140	
Apr	122	65	151	
Мау	137	73	138	
Jun	125	125	135	
Jul	113	107	137	
Aug	119	118	139	
Sep	118	124	142	
Oct	132	104	146	
Nov	141	102	154	
Dec	115	117	133	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average





Week sample taken**	Year sample taken		
	2017-2019*	2021/2022	
11/12/2021	36	40	
18/12/2021	30	59	
25/12/2021	16	33	
01/01/2022	33	19	
08/01/2022	34	30	
15/01/2022	34	44	
22/01/2022	33	43	
29/01/2022	35	39	
05/02/2022	35	32	
12/02/2022	31	22	
19/02/2022	35	37	
26/02/2022	35	53	


\* Average samples per year rounded to the nearest integer.

# **BOWEL CANCER (SCREENING AGE)**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-1.4%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	70	85	46	77
Feb	59	62	62	62
Mar	63	73	74	
Apr	62	37	71	
Мау	73	29	71	
Jun	61	66	73	
Jul	54	59	72	
Aug	58	40	64	
Sep	60	57	73	
Oct	75	46	83	
Nov	70	57	78	
Dec	56	59	72	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average





Week sample taken**	Year sample taken		
	2017-2019*	2021/2022	
11/12/2021	16	15	
18/12/2021	12	28	
25/12/2021	6	14	
01/01/2022	13	9	
08/01/2022	17	16	
15/01/2022	16	23	
22/01/2022	18	18	
29/01/2022	11	18	
05/02/2022	15	13	
12/02/2022	14	7	
19/02/2022	18	19	
26/02/2022	15	25	


\* Average samples per year rounded to the nearest integer.

### LUNG CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


<sup>-25.8%</sup> 



Month sample	Year sample taken			
taken	2017-2019*	2020	2021	2022
Jan	83	95	36	53
Feb	75	83	58	56
Mar	79	62	49	
Apr	79	36	65	
Мау	91	59	66	
Jun	80	84	73	
Jul	84	67	66	
Aug	88	86	62	
Sep	97	61	64	
Oct	88	53	56	
Nov	89	64	86	
Dec	61	60	54	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average





19/02/2022	16		
26/02/2022	27		
* Average samples per year rounded to the pearest integer			

\* Average samples per year rounded to the nearest integer.

\*\* Date shown refers to the end date of the week in 2021-2022. Data for previous years refers to the equivalent Sat-Sun week in those years.

21

22

20

21

31

24

17

14

14

23

16

17

17

20

17 17

01/01/2022

08/01/2022

15/01/2022

22/01/2022

29/01/2022

05/02/2022


12/02/2022

### FEMALE BREAST CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average

-3.2%



Month sample	Year sample taken			
taken	2017-2019*	2020	2021	2022
Jan	290	245	272	237
Feb	237	246	242	255
Mar	273	235	314	
Apr	242	187	280	
Мау	290	139	320	
Jun	247	201	342	
Jul	253	213	281	
Aug	271	232	232	
Sep	263	292	299	
Oct	277	265	242	
Nov	272	257	274	
Dec	261	286	254	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average



<sup>-4.4%</sup> 

Week sample taken**	Year sample taken		
	2017-2019*	2021/2022	
11/12/2021	92	93	
18/12/2021	82	89	
25/12/2021	22	60	
01/01/2022	83	22	
08/01/2022	69	48	
15/01/2022	67	62	
22/01/2022	80	74	
29/01/2022	81	75	
05/02/2022	77	77	
12/02/2022	60	75	
19/02/2022	74	45	
26/02/2022	63	93	


\* Average samples per year rounded to the nearest integer.

# FEMALE BREAST CANCER (SCREENING AGE)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-3.1%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	180	157	149	122
Feb	148	161	162	139
Mar	164	162	210	
Apr	149	125	179	
Мау	177	74	208	
Jun	154	101	218	
Jul	150	103	159	
Aug	160	153	149	
Sep	176	208	191	
Oct	198	165	171	
Nov	173	189	167	
Dec	151	167	167	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average





Wool comple token**	<b>F</b>			
Week sample taken**	2017-2019*	2021/2022		
11/12/2021	46	54		
18/12/2021	41	50		
25/12/2021	12	35		
01/01/2022	41	8		
08/01/2022	39	20		
15/01/2022	36	25		
22/01/2022	43	34		
29/01/2022	43	37		
05/02/2022	37	38		
12/02/2022	32	33		
19/02/2022	41	24		
26/02/2022	32	42		


\* Average samples per year rounded to the nearest integer.

### **PROSTATE CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average

-7.3%



Month sample	Year sample taken			
taken	2017-2019*	2020	2021	2022
Jan	85	82	47	83
Feb	64	73	53	61
Mar	82	72	124	
Apr	66	42	70	
Мау	97	81	77	
Jun	77	74	97	
Jul	83	41	48	
Aug	68	44	59	
Sep	66	54	92	
Oct	99	58	65	
Nov	88	140	96	
Dec	59	83	70	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average



<sup>+6.4%</sup> 

Week sample taken**	Year sample taken		
	2017-2019*	2021/2022	
11/12/2021	30	26	
18/12/2021	20	23	
25/12/2021	3	14	
01/01/2022	19	7	
08/01/2022	28	23	
15/01/2022	19	26	
22/01/2022	25	23	
29/01/2022	23	36	
05/02/2022	25	26	
12/02/2022	18	31	
19/02/2022	24	16	
26/02/2022	17	16	


\* Average samples per year rounded to the nearest integer.

# **UPPER GASTROINTESTINAL CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-4.9%



Month sample	e Year sample taken			
taken	2017-2019*	2020	2021	2022
Jan	41	54	28	39
Feb	40	38	27	34
Mar	42	32	54	
Apr	39	16	40	
May	39	28	38	
Jun	38	45	46	
Jul	42	31	45	
Aug	39	24	29	
Sep	47	36	49	
Oct	37	40	48	
Nov	41	41	48	
Dec	33	39	52	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>+9.1%</sup> 



\* Average samples per year rounded to the nearest integer.

\*\* Date shown refers to the end date of the week in 2021-2022. Data for previous years refers to the equivalent Sat-Sun week in those years.

9

12

8

14

19/02/2022


26/02/2022

# GYNAECOLOGICAL CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-17.1%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	101	97	54	73
Feb	84	70	64	90
Mar	91	76	80	
Apr	77	51	56	
Мау	104	60	68	
Jun	102	70	81	
Jul	94	69	84	
Aug	104	68	104	
Sep	90	77	85	
Oct	98	82	87	
Nov	93	90	108	
Dec	80	89	88	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>-3.3%</sup> 



11/12/2021252818/12/2021192025/12/202172301/01/2022281208/01/2022211915/01/2022272722/01/2022241429/01/2022252512/02/2022192519/02/20222720	-	2017-2019*	2021/2022
25/12/202172301/01/2022281208/01/2022211915/01/2022272722/01/2022241429/01/2022261905/02/2022252512/02/2022192519/02/20222128	11/12/2021	25	28
01/01/2022281208/01/2022211915/01/2022272722/01/2022241429/01/2022261905/02/2022252512/02/2022192519/02/20222128	18/12/2021	19	20
08/01/2022211915/01/2022272722/01/2022241429/01/2022261905/02/2022252512/02/2022192519/02/20222128	25/12/2021	7	23
15/01/2022272722/01/2022241429/01/2022261905/02/2022252512/02/2022192519/02/20222128	01/01/2022	28	12
22/01/2022241429/01/2022261905/02/2022252512/02/2022192519/02/20222128	08/01/2022	21	19
29/01/2022261905/02/2022252512/02/2022192519/02/20222128	15/01/2022	27	27
05/02/2022252512/02/2022192519/02/20222128	22/01/2022	24	14
12/02/2022192519/02/20222128	29/01/2022	26	19
<b>19/02/2022</b> 21 28	05/02/2022	25	25
	12/02/2022	19	25
<b>26/02/2022</b> 27 20	19/02/2022	21	28
	26/02/2022	27	20


\* Average samples per year rounded to the nearest integer.

# HEAD AND NECK CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-14.1%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	52	54	44	42
Feb	36	33	64	33
Mar	39	35	60	
Apr	42	18	42	
Мау	50	24	38	
Jun	51	32	47	
Jul	40	46	30	
Aug	46	36	38	
Sep	44	37	39	
Oct	54	41	37	
Nov	51	47	33	
Dec	50	44	46	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average





8

15

11

6 9 8

8

13

10

7

\* Average samples per year rounded to the nearest integer. \*\* Date shown refers to the end date of the week in 2021-2022. Data for previous years refers to

29/01/2022

05/02/2022

12/02/2022

19/02/2022


26/02/2022

# **URINARY CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-6.2%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	80	73	68	70
Feb	81	72	50	68
Mar	75	78	76	
Apr	79	40	93	
Мау	79	61	105	
Jun	77	100	81	
Jul	71	85	80	
Aug	78	69	66	
Sep	78	68	76	
Oct	78	54	70	
Nov	76	74	75	
Dec	68	58	60	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>-4.9%</sup> 



\* Average samples per year rounded to the nearest integer.

\*\* Date shown refers to the end date of the week in 2021-2022. Data for previous years refers to the equivalent Sat-Sun week in those years.

20

28

19

21

28

29

25

25

24

26

29/01/2022

05/02/2022

12/02/2022 19/02/2022


26/02/2022

# HAEMATOLOGICAL CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-0.3%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	72	97	64	60
Feb	59	81	88	69
Mar	73	85	87	
Apr	78	49	86	
Мау	96	58	90	
Jun	81	88	102	
Jul	73	83	83	
Aug	76	73	79	
Sep	75	89	95	
Oct	92	67	64	
Nov	88	80	82	
Dec	75	87	63	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

-9.7%



\* Average samples per year rounded to the nearest integer.

\*\* Date shown refers to the end date of the week in 2021-2022. Data for previous years refers to the equivalent Sat-Sun week in those years.

15

17


26/02/2022

### MELANOMA

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average

-9.1%



Month sample	sample Year sample taken			
taken	2017-2019*	2020	2021	2022
Jan	38	50	29	46
Feb	38	43	31	38
Mar	40	54	34	
Apr	40	29	44	
Мау	41	17	36	
Jun	38	27	46	
Jul	44	22	33	
Aug	36	39	44	
Sep	44	38	46	
Oct	49	21	52	
Nov	47	48	64	
Dec	38	32	26	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average



+0.8%

Wools commis tolson**	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	14	10	
18/12/2021	11	11	
25/12/2021	4	4	
01/01/2022	9	3	
08/01/2022	6	8	
15/01/2022	12	15	
22/01/2022	10	12	
29/01/2022	10	11	
05/02/2022	14	13	
12/02/2022	10	11	
19/02/2022	10	8	
26/02/2022	10	15	


\* Average samples per year rounded to the nearest integer.

# NON-MELANOMA SKIN CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


-27.2%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	652	759	398	444
Feb	561	577	405	394
Mar	550	495	470	
Apr	520	95	504	
Мау	599	236	423	
Jun	594	436	497	
Jul	514	383	366	
Aug	549	374	398	
Sep	641	488	532	
Oct	663	494	482	
Nov	692	577	538	
Dec	499	410	408	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>-24.7%</sup> 



Waals commis tolson**	Year sample taken		
Week sample taken**	2017-2019*	2021/2022	
11/12/2021	187	146	
18/12/2021	167	138	
25/12/2021	27	94	
01/01/2022	124	30	
08/01/2022	181	93	
15/01/2022	170	126	
22/01/2022	185	154	
29/01/2022	182	132	
05/02/2022	186	129	
12/02/2022	147	142	
19/02/2022	174	100	
26/02/2022	149	130	


\* Average samples per year rounded to the nearest integer.

### **OTHER CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to February 2022 compared to expected number based on 2017-2019 average


+0.8%



Month sample		Year sam	ple taken	
taken	2017-2019*	2020	2021	2022
Jan	106	86	103	102
Feb	84	83	94	87
Mar	92	105	113	
Apr	87	51	86	
Мау	95	69	118	
Jun	90	94	107	
Jul	91	110	90	
Aug	91	75	77	
Sep	91	133	90	
Oct	106	106	93	
Nov	101	97	96	
Dec	89	81	86	

Percentage change in the twelve weeks up to 26/02/2022 compared to expected number based on 2017-2019 average

<sup>+0.3%</sup> 



Wools comple tolson**	Year sample taken			
Week sample taken**	2017-2019*	2021/2022		
11/12/2021	30	21		
18/12/2021	28	19		
25/12/2021	9	32		
01/01/2022	20	10		
08/01/2022	25	20		
15/01/2022	26	31		
22/01/2022	33	30		
29/01/2022	25	30		
05/02/2022	27	34		
12/02/2022	18	29		
19/02/2022	23	14		
26/02/2022	26	21		

\* Average samples per year rounded to the nearest integer.

#### 1. NMSC: Non-melanoma skin cancer

2. Data is sourced from the four NHS pathology laboratories in Northern Ireland (Altnagelvin, Antrim, Belfast, Craigavon), which is provided to the NI Cancer Registry on a monthly basis. It does not include information on pathology samples processed by private laboratories.

3. Figures represent the number of pathology samples that indicated a malignant tumour and had this result coded and recorded by the end of February 2022. Due to potential reporting delays, pathology data from the month following February 2022 are used in compiling the presented results.

4. Assignment of week number is based upon a Sunday to Saturday week. The week ending label used in graphs and tables is based upon the date of the end of the week (a Saturday) in 2021-2022. This is compared with the equivalent Sunday-Saturday week in 2017-2019, although the actual date ending this week in 2017-2019 will differ.

5. Cancer types are defined as follows:

Bowel cancer: Includes colon, rectum and rectosigmoid junction (ICD10 codes: C18-C20).

Lung cancer: Includes lung and trachea (ICD10 codes: C33-C34).

Breast cancer: Includes female breast only (ICD10 codes: C50).

Prostate cancer: (ICD10 codes: C61).

**Gynaecological cancer:** Includes uterus, ovary, cervix, vulva, vagina, placenta and other female genital (ICD10 codes: C51-C58).

Upper GI cancer: Includes oesophagus and stomach (ICD10 codes: C15, C16).

**Head and neck cancer:** Includes lip, tongue, mouth, parotid & salivary glands, tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx, nasal cavity, middle ear, sinuses and larynx (ICD10 codes: C00-C14, C30-C32).

**Urinary cancer:** Includes kidney, renal pelvis, ureter, bladder and other urinary (ICD10 codes: C64-C68). **Haematological cancer:** Includes lymphoma (all types), leukaemia (all types), myeloma, malignant immunoproliferative disease and other lymphoid and haematopoietic (ICD10 codes: C81-C96). **Melanoma:** (ICD10 code: C43).

Non-melanoma skin cancer (NMSC): (ICD10 code: C44).

**Other cancer:** Includes cancers of small intestine, anus, liver, gallbladder, thymus, bone, mesothelioma, soft tissue, penis, testis, eye, brain, endocrine system and thyroid (ICD10 codes: C16, C21-C26, C37-C41, C45-C49, C60, C62, C63, C69-C75). Excludes cancer of unknown primary.